Sildenafil
Product Images NDC 68071-2898

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Sildenafil (NDC 68071-2898). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2898 3)

Label for Sildenafil 50 mg tablets from NuCare Pharmaceuticals, Inc. The package contains 30 tablets. The label includes NDC 68071-2898-3 and advises consulting the manufacturer's label for full ingredients. Storage instructions indicate controlled temperature 68-77°F. The label also warns to keep out of reach of children and states Rx Only.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 1)

Chemical structure of Sildenafil, showing the arrangement of atoms and bonds characteristic of this active ingredient in the depicted pharmaceutical product.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 2)

A line chart depicting changes in systolic blood pressure (mmHg) over 24 hours post-dose, comparing Sildenafil 100 mg and placebo. The x-axis represents time post dose in hours, and the y-axis shows systolic blood pressure changes. Two lines with distinct markers represent the two groups.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 3)

A line graph showing change in systolic blood pressure (SBP) in mmHg over time post dose (hours) comparing two treatments: Doxazosin plus Placebo and Doxazosin plus Sildenafil 25 mg. The graph tracks changes from 0 to 8 hours post dose, with SBP changes ranging approximately from 0 to -40 mmHg.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 4)

A line chart depicting the change in systolic blood pressure (SBP) over time in hours post dose. Two data series compare Doxazosin + Placebo and Doxazosin + Sildenafil 50 mg, showing their effects on SBP change from 0 to 8 hours post dose.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 5)

A line graph comparing the change in mmHg over time after dosing (hours) between two groups: one receiving Doxazosin + Sildenafil 100 mg and the other receiving Doxazosin + Placebo. Data points show trends from 0 to 8 hours post-dose with measures on the y-axis ranging approximately from -50 to 40 mmHg.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 6)

A pharmacokinetic curve showing plasma concentrations (ng/ml) of Sildenafil over time post dose (hours). The graph tracks concentrations from 0 to 24 hours after administering a commercial tablet, illustrating a peak shortly after dosing followed by a gradual decline.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 7)

A bar chart titled 'Effect of sildenafil on Maintenance of Erection by Baseline Score' showing the percentage of patients at endpoint on the vertical axis and baseline scores from 0 to 5 on the horizontal axis. Multiple bars represent different scores at endpoint, illustrating patient response variations across baseline scores for sildenafil.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 8)

A bar chart titled 'Effect of Placebo on Maintenance of Erection by Baseline Score' showing the percentage of patients at endpoint on the y-axis and baseline scores from 0 to 5 on the x-axis. Different baseline scores are represented by grouped bars indicating varying percentages of patients across the scores.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 9)

A bar graph depicting the percentage of patients reporting improvement across different treatment groups. The groups include Placebo (24%, n=463), Sildenafil 25 mg (63%, n=214), Sildenafil 50 mg (74%, n=391), and Sildenafil 100 mg (82%, n=380). The x-axis shows treatment groups and the y-axis shows the percentage of patients reporting improvement. The overall treatment p-value is less than 0.0001.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.